Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate the safety and tolerability of AZD8055 intermittent dosing schedules when
given orally to patients with advanced solid malignancies and lymphomas. Two intermittent
dosing schedules will be explored with increasing doses until a maximum tolerated dose is
determined for each schedule.